Core A (Administration) will have overall responsibility for: (A). Administration of the Program Project: """"""""Experimental Therapeutics and BioMonitoring for Brain Tumors."""""""" This will include oversight of science, thematic goals, specimen allocation, personnel, finances and interactions. A project tracking system, interaction log and regular schedule of meetings and reviews insures productive high quality synergies between the three Projects and three Cores. These reviews and interactions include monthly web-based conferences, meetings with the Project and Core Leaders, interaction with Drs. Breakefield and Carter and Messer for thematic evaluation and definitions of end-points of study as well as consultations with the Internal Advisory committee members. Yearly review will be maintained by an External Advisory Board which will be convened. A portion of the Core B Biorepository will reside at the MGH under the aegis of Dr. Hochberg within Core A. (B). Neuropathologic oversight (Stemmer-Rachamimov) of veterinary studies (P1, Core C) and human studies as well as GBM cohorts resides within the Core A. (C). Statistical oversight resides in Core B (Messer) but local (Core A and Project 2,3) assistance is provided by Mrs. Muzikansky (Core A). The latter includes data sharing and pre-publication review. An experienced Scientific Program Manager will support Program Integration and Management by tracking Aims and agenda for monthly conferences.

Public Health Relevance

This Core will provide the cohesion and oversight critical for co-ordinating a multi-institutional effort to evaluate therapeutic initiatives and biomarkers for gliomas. This will serve to increase the relevance and rigor of findings from this P01 to maximize its impact on therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Ricklefs, Franz L; Alayo, Quazim; Krenzlin, Harald et al. (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4:eaar2766
Park, Jongmin; Im, Hyungsoon; Hong, Seonki et al. (2018) Analyses of Intravesicular Exosomal Proteins Using a Nano-Plasmonic System. ACS Photonics 5:487-494
Antoury, Layal; Hu, Ningyan; Balaj, Leonora et al. (2018) Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun 9:3906
Zhou, Shuang; Appleman, Vicky A; Rose, Christopher M et al. (2018) Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Sci Alliance 1:e201800029
Min, Jouha; Nothing, Maria; Coble, Ben et al. (2018) Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis. ACS Nano 12:3378-3384
Lee, Kyungheon; Fraser, Kyle; Ghaddar, Bassel et al. (2018) Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano 12:494-503
ReƔtegui, Eduardo; van der Vos, Kristan E; Lai, Charles P et al. (2018) Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nat Commun 9:175
Speranza, Maria-Carmela; Passaro, Carmela; Ricklefs, Franz et al. (2018) Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol 20:225-235
Boussiotis, Vassiliki A; Charest, Alain (2018) Immunotherapies for malignant glioma. Oncogene 37:1121-1141
Sahin, Ayguen; Sanchez, Carlos; Bullain, Szofia et al. (2018) Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS One 13:e0199414

Showing the most recent 10 out of 223 publications